Scars Clinical Trial
Official title:
A Phase I Open-labeled, Single-arm, Single-centred Study to Test the Safety of ADSC-SVF-002 in Subjects With Soft Tissue Defects or Abnormal Wound Healing
Verified date | July 2017 |
Source | AdiSave Inc. |
Contact | Keren Leibson, PhD |
Phone | 416 785-7536 |
info[@]adisave.com | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A single-arm, open-labeled, single-center, descriptive and exploratory safety trial using ADSC-SVF-002. ADSC-SVF-002 is an autologous adipose derived stem cell (ADSC)-containing stromal vascular fraction (SVF) obtained from subcutaneous fat harvested by liposuction from a patient. As a cellular therapy product, ADSC-SVF-002 (fresh or cryopreserved) will be administered subcutaneously via injection, with or without unprocessed autologous fat (fresh or cryopreserved), into soft tissue defects and abnormally healing wounds. The primary objective of the trial is to demonstrate the safety of ADSC-SVF-002 in a population of subjects with soft tissue defects or abnormal wound healing who are still symptomatic despite being managed by conventional therapies.
Status | Not yet recruiting |
Enrollment | 10 |
Est. completion date | January 2021 |
Est. primary completion date | October 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: 1. Subject has soft tissue deficiencies, soft tissue post traumatic malformations, scars, and/or abnormal wound healing. 2. Subject is an adult male or non-pregnant female between the ages of 18 to 80 years. 3. Subject is able to undergo a liposuction procedure in the opinion of the investigator or per facility guidelines. 4. Subject is able to read, understand and sign a written Informed Consent to participate in the study. 5. Subject is willing and able to comply with the study protocol, including requirements for taking and abstaining from medications. Exclusion Criteria: 1. The subject is a woman of child-bearing potential (not surgically sterile or post-menopausal for at least 1 year as documented in medical history), but is not using a highly effective method of contraception [oral, injected or implanted hormonal methods of contraception; intrauterine device (IUD) or intrauterine system (IUS); condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository; or male sterilization (vasectomy)]. 2. Subject has a history of cancer and/or any known conditions/diseases prone to malignancy. 3. Subject has significant cardiac, renal, or hepatic failure or any other disease that may interfere with the ability to interpret the results of the study. 4. Subject has an infection, cellulitis, or osteomyelitis diagnosed by MRI and microbiologic culture results. 5. Subject has an autoimmune disorder. 6. Subject has a connective, metabolic or atrophic skin disease. 7. Subject is under chronic anticoagulant therapy. 8. Subject has a Body Mass Index (BMI) >30. 9. Subject is positive for HBs antigen, HCV antibody, or HIV antibody. 10. Subject has received other investigational drug/drugs or unapproved medication within 3 months before registration in this study. 11. Subject has a history of hematopoietic stem cell transplantation or radio immunotherapy. 12. Subject has a recent and significant weight loss, the cause of which has not been determined. 13. Subject has a history of hereditary linked malignancy in a first-degree relative (parent, child, sibling). 14. Subject is participating in another clinical trial within 6 weeks prior to registration in this study. 15. Subject has a psychiatric disorder that in the judgment of the investigator could interfere with provision of informed consent, completion of tests, therapy, or follow-up. |
Country | Name | City | State |
---|---|---|---|
Canada | Forest Hill Institute of Aesthetic Plastic Surgery | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
AdiSave Inc. |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Continuous monitoring of safety via laboratory tests and physical examinations | Continuous monitoring of safety as requested by Health Canada | Screening, 48 hours after procedure, and at post-treatment months 1, 2 and 6 | |
Secondary | Physician satisfaction with wound cosmesis, assessed using the Hollander Wound Evaluation Scale | Screening, 48 hours after procedure, and at post-treatment day 10 and months 1-6 | ||
Secondary | Patient satisfaction with wound cosmesis, assessed using the 100 mm vertical line visual analogue scale | Screening, 48 hours after procedure, and at post-treatment day 10 and months 1-6 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04806594 -
Clinical Investigation on the Safety and Clinical Performance of Papix Acne Scar.
|
N/A | |
Completed |
NCT01700595 -
Preexpanded Perforator Flaps in Children
|
N/A | |
Recruiting |
NCT03782038 -
Study to Evaluate the Efficacy of a Micro Coring Device for the Treatment of Scars of the Cytrellis Micro-Coring Device for the Treatment of Scars
|
N/A | |
Recruiting |
NCT06202274 -
Clinical Study to Evaluate the Safety and Efficacy of Candela Technology
|
N/A | |
Completed |
NCT01932359 -
Rapidly Absorbable Versus Non-absorbable Sutures for Mohs Surgery Repair on the Face: a Randomized Controlled Split-scar Study
|
N/A | |
Completed |
NCT01091181 -
The Effect of Hysterotomy Technique on the Rate of Large Defects in the Hysterotomy Scar
|
N/A | |
Unknown status |
NCT00969475 -
The Effects of Fractional Carbon Dioxide (CO2) Laser Treatment Prior to Wound Closure
|
N/A | |
Recruiting |
NCT06021275 -
Microneedling With Regular Insulin Versus Microneedling Alone in Treatment of Atrophic Scars
|
N/A | |
Recruiting |
NCT02195063 -
Survey Study for Pain Management, Wound Care, Scar Care or UDT
|
Phase 4 | |
Terminated |
NCT00803140 -
Cutaneous Scarring of Scalpel Versus Cautery
|
N/A | |
Not yet recruiting |
NCT04593706 -
Comparison of the Efficacy of Different Steroids in the Treatment of Abnormal Scars (Keloids, Hypertrophic Scars)
|
N/A | |
Recruiting |
NCT05847530 -
Pilot Evaluation of the Cynosure Potenza™ System for Treatment of Cosmetic Dermatologic Skin Conditions
|
N/A | |
Withdrawn |
NCT01350739 -
The Umbilical Access in Laparoscopic Surgery
|
N/A | |
Completed |
NCT02145130 -
Phase I Study for Autologous Dermal Substitutes and Dermo-epidermal Skin Substitutes for Treatment of Skin Defects
|
Phase 1 | |
Completed |
NCT01358838 -
Ablative 10600 nm Fractional Laser Therapy for the Treatment of Scars
|
N/A | |
Completed |
NCT03880058 -
Safety and Efficacy of SLI-F06 in Wound Healing and Scar Appearance
|
Phase 1/Phase 2 | |
Recruiting |
NCT05528328 -
Post-surgical Scars After the Use of CACIPLIQ20
|
Phase 3 | |
Completed |
NCT00450775 -
Evaluation of the Efficacy, Tolerability, and Patient Acceptance of Dermatix Q for the Prevention and Management of Scars
|
Phase 4 | |
Completed |
NCT00580736 -
Optical Clearing of the Skin in Conjunction With Laser Treatments
|
Phase 1 | |
Withdrawn |
NCT04269317 -
Clinical Study to Evaluate the Safety and Effectiveness of the Treatment With Tixel C on Acne Scars
|
N/A |